International Journal of Chronic Obstructive Pulmonary Disease
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The association between COPD and heart failure risk: a review
(3853) Total Article Views
Authors: de Miguel Díez J, Chancafe Morgan J, Jiménez García R
Published Date June 2013
Volume 2013:8 Pages 305 - 312
|Received:||28 February 2013|
|Accepted:||12 April 2013|
|Published:||28 June 2013|
1Pulmonology Department, Gregorio Maranon University Hospital, Complutense University of Madrid, Madrid, Spain; 2Preventive Medicine and Public Health Teaching and Research Unit, Department of Health Sciences, Rey Juan Carlos University, Madrid, Spain
Abstract: Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective ß1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled ß2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.
Keywords: chronic obstructive pulmonary disease, heart failure
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Javier de Miguel-Díez
Readers of this article also read:
- Journal Indexing
See where all the Dove Press journals are indexed.
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions